U.S. Markets open in 6 hrs 21 mins

Rosetta Genomics Ltd. (ROSG)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.62+0.04 (+1.55%)
At close: 3:59PM EDT
People also watch
RXIIPSTICLSNOPXAGENE
  • KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    Products

    Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.

    Market

    Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.

  • Reveal is real. I'm a recent investor to ROSG with an average buy-in price of around $2.85 and now have substantial ownership of ROSG.. Both my father and my sister had thyroid surgery because their lab tests came back as "indeterminate". Fortunately both cases were benign ! The point being that Reveal could likely have saved $10,000's to the insurance company.
    This product alone is worth a $40+ million valuation now that its approved and marketed, not to mention all the other IP. ROSG at these price levels is a crazy bargain and someone has figured it out and is accumulating. Last chance to buy at these levels in my opinion!!!
  • Michael- We had 7.6 million in January. We should run out of cash by aug. 15 ( assuming same burn rate like last year )
    Hopefullly with some reduction in staff and reveal revenue the fund could last till sept 30.

    If personalized DX is sold it would buy another 6 weeks

    So Mr. Berlin will have some good announcement in July and he will follow that up with ATM. We need to get out before ATM.
  • I predict we will hear about the sale of PersonalizedDx in July or August and it will bring in a lot more money than many of you are expecting - giving the company some very solid non-dilutive funding. I believe there are quite a few entities out there bidding for PersonalizedDex.
  • Told you guys that Reveal is the real deal, but a lot of you aren't listening. Well, some folks are listening, as is evident by the share price climb since May. We are just getting started. Remember, Afirma does $16M in revenues PER quarter. Reveal could get there a few years down the road. Or Veracyte could simply #$%$ up Rosetta, but I hope not, because I believe Rosetta has turned the corner on a tremendous market opportunity.
  • 3 strait days of accumulation and AH/premarket trading... broker has August as the ER
  • can't really fly...all waiting fir dilution headline
  • Peeps are pumping, u have been warned, company is a joke run by a greedy clown!
  • Another accumulation day... Been like this since 1.4.
  • Lost 85% of my investment in less than 2 years (60,000) yet people say "butt hurt bag holders" yes it hurts, yes I sold, it would have to go up 7 fold for me to break even. The head of the company get compensated insanely while the investor gets screwed.
  • Wow. Mr. Berlin's hard work has brought us back to 20 cents.
  • if Reveal becomes the standard of care in the space, overtaking Veracyte's Afirma, do you have any idea how much profit you will make on this stock from here? I imagine Veracyte would wanna buy it, thought I'd rather see the company develop Reveal into the game changer that it is and the tremendous other molecular diagnostic IP they have.
  • wow 5m market....awesome what a joke
  • Bad market day yet we're up, ... something up?
  • I've seen a few people who have been here for 2 years plus. They bought in around $4-6 pre split and sold at $1.4 - $1.6 area after the 1:12 split. Great short play guys!
  • There are in fact two things, science and opinion; the former begets knowledge, the latter ignorance. http://dataunion.tistory.com/3108

    Rosetta Genomics Ltd. NASDAQ : ROSG Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.6 In other words, the correlation coefficient of the other stoc
    dataunion.tistory.com
  • * steal .... Reveal revenues (according to the company, which I know many of you are doubtful) are expected to increase from $850,000 in '16 to $4,000,000 to $5,000,0000 in '17. That is sick growth, folks. At a miniscule MC cap of like $5-6 million and almost no debt, you are crazy not to be in now.
  • Patent news ? He has not resigned yet ? Thought he would move along with personalizedDX.
  • I hope it's not a buyout. A few weeks ago I said this was a still in the $1s and some of you scoffed at me. I feel bad that for years many investors got burned here, but with these tiny companies, it happens a lot. It's a lengthly process. But folks, $ROSG finally has a real winner in the Rosetta Reveal. Read the journal articles. Look at the revenues. No additional biopsies. Accuracy results better than Veracyte in differentiating non-malignant thyroid nodules. Do you folks have any idea how much revenue Veracyte's Afirma does per quarter? Like $16M. Say what you want, but little Rosetta, with Reveal (which just launched last year, mind you) has the superior classifier! I know the company needs money, but I suspect with their treasure trove of IP and PersonalizedDx they will get it, and with Rosetta Reveal, who knows how high this may fly. It is a screaming buy at these levels.
  • Buyout on the horizon..... just too much value in this company for a BK..... trading patterns in the last week indicate a steady accumulation... Last chance to buy at these levels is my opinion !